Patisiran

3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
Mon, 03/26/18 - 10:45 am
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
Thu, 03/22/18 - 09:21 am
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Yahoo/Motley Fool
Mon, 01/15/18 - 09:35 am
Alnylam
givosiran
Patisiran
Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran
Endpoints
Mon, 01/8/18 - 09:45 am
Alnylam
Sanofi
JPMHC 2018
Patisiran
FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency
Endpoints
Mon, 11/20/17 - 07:45 pm
FDA
Alnylam
Patisiran
breakthrough status
Alnylam Starts Rolling NDA Submission for RNAi Candidate
Yahoo/Zacks.com
Fri, 11/17/17 - 11:15 am
Alnylam
RNAi
hereditary ATTR amyloidosis
FDA
Patisiran
Alnylam outshines Ionis with RNAi drug
BioPharma Dive
Sat, 11/4/17 - 08:40 am
Alnylam
Ionis Pharmaceuticals
RNAi
Sanofi
Patisiran
amyloidosis
A drug 15 years in the making: Alnylam's quest to prove RNAi
BioPharma Dive
Sat, 09/30/17 - 10:16 am
Alnylam
RNAi
Patisiran
Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines
Stat
Wed, 09/20/17 - 09:27 am
Alnylam
rare disease
Patisiran
familial amyloid polyneuropathy
RNAi
5 Biotech Stocks With Major Catalysts in July
Motley Fool
Wed, 06/28/17 - 11:03 pm
biotech
AcelRx
Zalviso
Alnylam
Patisiran
Dynavax
HEPLISAV-B
GSK
Benlysta
Puma Biotechnology
neratinib
5 Biotech Stocks On Deck With The FDA
Yahoo/Benzinga
Tue, 06/30/15 - 06:13 pm
FDA
Alnylam
Patisiran
Esperion Therapeutics
ETC-1002
Intercept Pharmaceuticals
obeticholic acid
Sarepta Therapeutics
eteplirsen
Tekmira
TKM-PLK1
Alnylam's star RNAi drug keeps the pace on the way to Phase III
Fierce Biotech
Tue, 04/21/15 - 12:20 pm
Alnylam
RNAi
Patisiran
ATTR
Alnylam Drug Scores Against Rare Nerve Disease
Investors.com
Mon, 10/13/14 - 04:02 pm
Alnylam
Patisiran
familial amyloid polyneuropathy
Sanofi Pays $700 Million for Alnylam Drugs and Stake
Bloomberg
Mon, 01/13/14 - 08:47 am
Sanofi
Alnylam
Patisiran
Alnylam earns $7M payment for patisiran Phase II 'success'
The Fly on the Wall
Mon, 11/25/13 - 10:44 am
Alnylam
Patisiran
Genzyme
Sanofi
Alnylam rises as FDA bestows fast-track status
Yahoo/AP
Mon, 11/11/13 - 02:13 pm
fast track
Alnylam
FDA
Patisiran
Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial
Yahoo/BusinessWire
Sun, 11/10/13 - 01:08 pm
Alnylam
Patisiran
amyloidosis
TTR-mediated amyloidosis

Pages